Edgestream Partners L.P. bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 245,207 shares of the company’s stock, valued at approximately $5,995,000. Edgestream Partners L.P. owned 0.24% of Beam Therapeutics at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in BEAM. Versant Capital Management Inc grew its holdings in Beam Therapeutics by 123.6% during the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock valued at $30,000 after purchasing an additional 685 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Beam Therapeutics during the 2nd quarter worth $43,000. Hollencrest Capital Management acquired a new position in Beam Therapeutics in the first quarter worth about $43,000. Fulcrum Asset Management LLP bought a new stake in shares of Beam Therapeutics in the 3rd quarter valued at approximately $51,000. Finally, Nykredit A S bought a new stake in Beam Therapeutics during the second quarter valued at $75,000. 99.68% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on BEAM shares. Canaccord Genuity Group decreased their price target on shares of Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Wedbush upped their target price on shares of Beam Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 11th. William Blair upgraded Beam Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Wall Street Zen downgraded Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.64.
Read Our Latest Stock Analysis on BEAM
Insider Activity at Beam Therapeutics
In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 3.80% of the company’s stock.
Beam Therapeutics Price Performance
BEAM opened at $21.01 on Thursday. Beam Therapeutics Inc. has a 12-month low of $20.23 and a 12-month high of $38.26. The firm has a market capitalization of $2.17 billion, a P/E ratio of -20.20 and a beta of 2.23. The company has a quick ratio of 13.00, a current ratio of 13.01 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average of $24.76 and a 200-day moving average of $27.74.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.11). The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $8.75 million. Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. Beam Therapeutics’s revenue was down 96.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.10) earnings per share. Equities analysts forecast that Beam Therapeutics Inc. will post -4.65 EPS for the current fiscal year.
Beam Therapeutics Profile
Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.
Read More
- Five stocks we like better than Beam Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
